MX2007014830A - Metodos y formulaciones para aumentar la absorcion y disminuir la variabilidad de absorcion de farmacos, vitaminas y nutrientes oralmente administrados. - Google Patents

Metodos y formulaciones para aumentar la absorcion y disminuir la variabilidad de absorcion de farmacos, vitaminas y nutrientes oralmente administrados.

Info

Publication number
MX2007014830A
MX2007014830A MX2007014830A MX2007014830A MX2007014830A MX 2007014830 A MX2007014830 A MX 2007014830A MX 2007014830 A MX2007014830 A MX 2007014830A MX 2007014830 A MX2007014830 A MX 2007014830A MX 2007014830 A MX2007014830 A MX 2007014830A
Authority
MX
Mexico
Prior art keywords
absorption
nutrients
vitamins
formulations
enhancing
Prior art date
Application number
MX2007014830A
Other languages
English (en)
Inventor
Curtis A Spilburg
Original Assignee
Zomanex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zomanex Llc filed Critical Zomanex Llc
Publication of MX2007014830A publication Critical patent/MX2007014830A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un método y la composición para preparar fármacos pobremente solubles en agua, hidrofóbicos, biodisponibles. Este utiliza por ejemplo, lecitina, esterol y solvente; se mezclan y luego el solvente se elimina, las proporciones utilizadas difieren unas de otras, y se eleva al máximo el funcionamiento.
MX2007014830A 2006-11-27 2007-11-26 Metodos y formulaciones para aumentar la absorcion y disminuir la variabilidad de absorcion de farmacos, vitaminas y nutrientes oralmente administrados. MX2007014830A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/563,356 US20080124387A1 (en) 2006-11-27 2006-11-27 Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients

Publications (1)

Publication Number Publication Date
MX2007014830A true MX2007014830A (es) 2009-02-19

Family

ID=39148632

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007014830A MX2007014830A (es) 2006-11-27 2007-11-26 Metodos y formulaciones para aumentar la absorcion y disminuir la variabilidad de absorcion de farmacos, vitaminas y nutrientes oralmente administrados.

Country Status (8)

Country Link
US (3) US20080124387A1 (es)
EP (1) EP1925294B1 (es)
JP (1) JP5225663B2 (es)
AU (1) AU2008203553B2 (es)
BR (1) BRPI0704205A2 (es)
CA (1) CA2612128C (es)
ES (1) ES2535076T3 (es)
MX (1) MX2007014830A (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
CN101888787A (zh) * 2007-12-05 2010-11-17 帝斯曼知识产权资产管理有限公司 脂溶性活性成分的粉状制剂
CA2822435C (en) * 2009-12-31 2018-09-11 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
ES2875458T3 (es) 2010-12-29 2021-11-10 Abbott Lab Producto nutricional para uso en la reducción de la incidencia de enterocolitis necrosante en un lactante, niño pequeño o niño
WO2014132134A1 (en) * 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CN105188670B (zh) 2013-03-15 2018-11-02 马留斯医药有限责任公司 乳液制剂
WO2015153449A1 (en) 2014-03-31 2015-10-08 Redshift Systems Corporation Fluid analyzer with modulation for liquids and gases
CA2963881C (en) * 2014-10-17 2022-05-03 Raisio Nutrition Ltd Cholesterol lowering capsules
JP6211220B1 (ja) * 2017-01-26 2017-10-11 アピ株式会社 カプセル用アントシアニン含有組成物及びカプセル剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (es) 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US4542019A (en) * 1983-03-11 1985-09-17 John Lezdey Antacid compositions
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
GB8714652D0 (en) * 1987-06-23 1987-07-29 Davis S S Drug emulsion
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
FR2619505B1 (fr) * 1987-08-20 1990-08-31 Dior Christian Parfums Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la pregnenolone ou un ester de pregnenolone, et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite regeneratrice ou revitalisante, l'incorporant
US5202126A (en) 1987-08-20 1993-04-13 Parfums Christian Dior Composition containing pregnenolone or a pregnenolone ester incorporated in liposomes, and a method for regenerating, or revitalizing the skin therewith
FR2623716B1 (fr) * 1987-11-27 1991-04-05 Lvmh Rech Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la tyrosine ou un derive de tyrosine et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite pigmentante, l'incorporant
US5290562A (en) 1987-11-27 1994-03-01 L V M H Recherche Compositions and methods employing liposomes including tyrosine or a tyrosine derivative
US5139803A (en) 1989-02-09 1992-08-18 Nabisco, Inc. Method and liposome composition for the stabilization of oxidizable substances
CA2150463A1 (en) * 1992-12-02 1994-06-09 Donald F. H. Wallach Extended duration antacid product
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
FI107015B (fi) 1996-08-09 2001-05-31 Raisio Benecol Oy Kasvistanolirasvahappoestereiden seos ja sen käyttö sekä elintarvike
EP0927025A4 (en) * 1996-09-18 2001-07-25 Dragoco Inc DRY POWDER COMPOSITION WITH ACTIVE INGREDIENT ENCLOSED IN LIPOSOMES
KR19980030438A (ko) * 1996-10-29 1998-07-25 김영환 반도체 버어니어 구조 및 그것을 이용한 오버레이 정확도 측정방법
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US6110502A (en) 1998-02-19 2000-08-29 Mcneil-Ppc, Inc. Method for producing water dispersible sterol formulations
US6087353A (en) * 1998-05-15 2000-07-11 Forbes Medi-Tech Inc. Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like
US6063776A (en) * 1998-05-26 2000-05-16 Washington University Sitostanol formulation with emulsifier to reduce cholesterol absorption and method for preparing and use of same
US5932562A (en) 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
US6242001B1 (en) 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
TWI290473B (en) * 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US20030129253A1 (en) * 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
US20030212046A1 (en) * 2002-05-07 2003-11-13 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
US20060093661A1 (en) 2002-05-07 2006-05-04 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
DK1830814T3 (da) * 2005-01-06 2009-08-03 Cima Labs Inc Smagsmaskeret formulering til ikke-plastificerende lægemidler
KR101430767B1 (ko) * 2005-07-18 2014-08-19 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
BRPI0704205A2 (pt) 2010-09-08
AU2008203553A1 (en) 2008-10-23
AU2008203553B2 (en) 2010-10-28
CA2612128C (en) 2012-01-31
CA2612128A1 (en) 2008-05-27
EP1925294B1 (en) 2015-04-08
JP5225663B2 (ja) 2013-07-03
US20110111009A1 (en) 2011-05-12
EP1925294A1 (en) 2008-05-28
JP2008133281A (ja) 2008-06-12
US20080124387A1 (en) 2008-05-29
US20150030671A1 (en) 2015-01-29
ES2535076T3 (es) 2015-05-05

Similar Documents

Publication Publication Date Title
MX2007014830A (es) Metodos y formulaciones para aumentar la absorcion y disminuir la variabilidad de absorcion de farmacos, vitaminas y nutrientes oralmente administrados.
WO2006015081A3 (en) A PROCESS FOR THE PREPARATION OF 7α-ALKYLATED 19-NORSTEROIDS
IL190646A (en) Multifunctional June Liquid Preparations, Including Pharmaceutical, Bioactive, Nutritional and Energetic Vehicles and Method for Preparing
AU2003242988A1 (en) Process for the preparation of the anti-cancer drug imatinib and its analogues
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
EP3002274A8 (en) Treprostinil monohydrate
WO2008007152A3 (en) Preparation of pharmaceutical formulations
WO2008037557A3 (en) Rapidly solubilising formulation of non-steroidal anti-inflammatory drugs
WO2007121318A3 (en) Formulations for delivering insulin
WO2007016388A3 (en) Liquid formulations for controlled delivery of benzisoxazole derivatives
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
EP2279732A3 (en) Compounds and compositions for delivering active agents
EP1637167A3 (en) New injectable formulations containing progesterone
WO2007036802A3 (en) Sublingual dosage form comrising vitamin d analogue, in particular calcitriol
WO2007075825A3 (en) Lipophilic anticancer drug compounds
WO2008145996A3 (en) Novel compounds and pharmaceutical preparations from neobeguea spec
WO2008030818A3 (en) Novel liposome compositions
WO2006113568A8 (en) Controlled delivery dosage form of tramadol and gabapentin
SI1742927T1 (sl) Derivati butanojske kisline, postopki za pripravo le-teh, farmacevtski sestavki, ki jih vsebujejo in terapevtske uporabe le-teh
MX2007003897A (es) Una formulacion farmaceutica que comprende insulina cristalina e insulina disuelta.
WO2009026257A3 (en) Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2006034147A3 (en) Compositions and methods for the preparation and administration of poorly water soluble drugs
TW200640932A (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
CA2483916A1 (en) Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
HK1120417A1 (en) Stable nanoparticle formulations

Legal Events

Date Code Title Description
FC Refusal